Personalized mRNA vaccine shows promise in reducing melanoma return: Research

A personalized mRNA vaccine developed by Moderna and Merck shows promise in reducing the recurrence of melanoma, the deadliest form of skin cancer, according to a five-year follow-up of a Phase 2b study.